INNOVATION IS THE
BEST MEDICINE
Built on a foundation of deep research, RTW invests with innovative companies looking to bring important new products to patients.
OUR FOCUS ON INNOVATIVE MEDICINE
We have developed expertise through our comprehensive study of industry and academic efforts in targeted areas of significant innovation. By focusing our energies, we believe we can add more value to entrepreneurs and scientists. Our current focus areas include both technology platforms and disease areas, and include:
Gene Therapy
Gene Therapy
Viruses have enabled the delivery of specific genes to tissues such as the liver, brain, muscle, and eye. We expect gene therapies to be successfully developed for many genetic diseases caused by insufficient gene expression.
Oligos
Oligos
Improvements in chemistry have allowed short sequences of RNA to be delivered to the liver and the brain. These oligos can be designed to inhibit or promote gene expression and have the potential to treat a variety of liver and neuromuscular diseases.
Cancer
Cancer
Immuno-oncology, cell, and targeted therapies are revolutionizing the treatment of many tumor types. We forecast these therapies will significantly extend life expectancy for approximately half of cancer patients over the coming decade.
Rare Disease
Rare Disease
Over seven thousand rare diseases have been identified, the vast majority of which do not have available therapies. Because the majority have relatively simple genetic causes, we expect significant progress to be made in the coming years.
OUR IN-DEPTH INSIGHT
THE FUTURE LOOKS BRIGHT
Thanks to the genome, drug innovation is clearly accelerating.
We are living in the middle of a cancer therapy revolution.
15,000+
Drugs in the
Pipeline
The number of new patents has inflected upward. This is translating into both more and better drugs in the pipeline.
500,000+
Lives Saved
Each Year
Cancer kills over 1 million people each year in the US and Europe. The coming decade could drop this number by over a third.
$100 Billion
New
Revenues
New therapeutic classes like checkpoint inhibitors, cell therapy, gene therapy, and oligos should lead to substantial new revenues.
$500 Billion
New Market
Capitalization
We expect half a trillion of new value creation for small and large companies in biotech and pharma.
OUR SUCCESSFUL PARTNERSHIPS
We support companies through the ups and downs of the often challenging journey to bring therapies to patients.
LET’S TALK
We believe biotech will be a key value creator over the next decade.
Contact us to learn more about RTW’s expertise, insight and experience in identifying and working with companies focused in areas of breakthrough innovation.